medcitynews.com
/4 weeks ago
Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition
Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a...
pharmexec.com
/1 month ago
<![CDATA[Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreeme...
fortworthbusiness.com
/3 weeks ago
The World’s Next Breakthrough in Eye Care Isn’t Just Innovation. It’s Capacity.
Few things are more fundamental to human potential than the ability to see. Sight helps us connect with others, navigate the world and live independently. Yet, a gap between what i...
biopharmadive.com
/6 days ago
J&J bets $2.2B on Ollin’s vision loss drug
The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.